Current Perspectives on Idiopathic Intracranial Hypertension without Papilloedema
- PMID: 34073844
- PMCID: PMC8225003
- DOI: 10.3390/life11060472
Current Perspectives on Idiopathic Intracranial Hypertension without Papilloedema
Abstract
The pseudotumor cerebri syndrome embraces disorders characterised by raised intracranial pressure, where the commonest symptom is headache (90%). Idiopathic intracranial hypertension without papilloedema (IIHWOP) is increasingly recognised as a source of refractory headache symptoms and resultant neurological disability. Although the majority of patients with IIHWOP are phenotypically similar to those with idiopathic intracranial hypertension (IIH), it remains uncertain as to whether IIHWOP is nosologically distinct from IIH. The incidence, prevalence, and the degree of association with the world-wide obesity epidemic is unknown. Establishing a diagnosis of IIHWOP can be challenging, as often lumbar puncture is not routinely part of the work-up for refractory headaches. There are published diagnostic criteria for IIHWOP; however, some report uncertainty regarding a pathologically acceptable cut off for a raised lumbar puncture opening pressure, which is a key criterion. The literature provides little information to help guide clinicians in managing patients with IIHWOP. Further research is therefore needed to better understand the mechanisms that drive the development of chronic daily headaches and a relationship to intracranial pressure; and indeed, whether such patients would benefit from therapies to lower intracranial pressure. The aim of this narrative review was to perform a detailed search of the scientific literature and provide a summary of historic and current opinion regarding IIHWOP.
Keywords: diplopia; headache; idiopathic intracranial hypertension without papilloedema; intracranial pressure; lumbar puncture; migraine; optical coherence tomography; pseudotumour cerebri; telemetric monitoring; tinnitus.
Conflict of interest statement
S.P. Mollan reports other Invex Therapeutics, other Heidelberg engineering during the conduct of the study; other from Chugai-Roche Ltd., other from Janssen, other from Allergan, other from Santen, other from Roche, other from Neurodiem, outside the submitted work. Y.J. Chong declares no competing interests. O. Grech reports other Invex Therapeutics. A.J. Sinclair reports salary and stock options from Invex therapeutics, during the conduct of the study. B.R. Wakerley reports other Invex Therapeutics.
Similar articles
-
Sinus venous stenosis-associated IIHWOP is a powerful risk factor for progression and refractoriness of pain in primary headache patients: a review of supporting evidences.Neurol Sci. 2011 May;32 Suppl 1:S169-71. doi: 10.1007/s10072-011-0536-1. Neurol Sci. 2011. PMID: 21533738 Review.
-
Endolymphatic hydrops in idiopathic intracranial hypertension: prevalence and clinical outcome after lumbar puncture. Preliminary data.Neurol Sci. 2017 May;38(Suppl 1):193-196. doi: 10.1007/s10072-017-2895-8. Neurol Sci. 2017. PMID: 28527079
-
Chronic fatigue syndrome and idiopathic intracranial hypertension: Different manifestations of the same disorder of intracranial pressure?Med Hypotheses. 2017 Aug;105:6-9. doi: 10.1016/j.mehy.2017.06.014. Epub 2017 Jun 24. Med Hypotheses. 2017. PMID: 28735654
-
Idiopathic Intracranial Hypertension Without Papilledema (IIHWOP) in Chronic Refractory Headache.Front Neurol. 2018 Jun 26;9:503. doi: 10.3389/fneur.2018.00503. eCollection 2018. Front Neurol. 2018. PMID: 29997572 Free PMC article.
-
Headache in idiopathic intracranial hypertension. A CGRP-dependent head pain?Neurol Sci. 2020 Dec;41(Suppl 2):417-421. doi: 10.1007/s10072-020-04641-w. Neurol Sci. 2020. PMID: 32852682 Review.
Cited by
-
Idiopathic Intracranial Hypertension in Neonates, Infants, and Toddlers.J Clin Med. 2025 Jul 17;14(14):5084. doi: 10.3390/jcm14145084. J Clin Med. 2025. PMID: 40725776 Free PMC article. Review.
-
Imaging the brain: diagnosis aided by structural features on neuroimaging studies.Eye (Lond). 2024 Aug;38(12):2380-2391. doi: 10.1038/s41433-024-03142-w. Epub 2024 May 23. Eye (Lond). 2024. PMID: 38783084 Free PMC article. Review.
-
Transverse Sinus Stenting Reverses Medically Refractory Idiopathic Intracranial Hypertension.Front Ophthalmol (Lausanne). 2022 Jun 21;2:885583. doi: 10.3389/fopht.2022.885583. eCollection 2022. Front Ophthalmol (Lausanne). 2022. PMID: 38983575 Free PMC article.
-
Idiopathic intracranial hypertension in Asians: a retrospective dual-center study.J Headache Pain. 2024 Sep 4;25(1):144. doi: 10.1186/s10194-024-01852-w. J Headache Pain. 2024. PMID: 39232671 Free PMC article.
-
An interdisciplinary integrated specialized one-stop outpatient clinic for idiopathic intracranial hypertension-a comprehensive assessment of clinical outcome.Eur J Neurol. 2024 Oct;31(10):e16401. doi: 10.1111/ene.16401. Epub 2024 Aug 16. Eur J Neurol. 2024. PMID: 39152571 Free PMC article.
References
-
- GBD. Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990‚ Äê2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
-
- Mollan S.P., Davies B., Silver N.C., Shaw S., Mallucci C.L., Wakerley B.R., Krishnan A., Chavda S.V., Ramalingam S., Edwards J., et al. Idiopathic intracranial hypertension: Consensus guidelines on management. J. Neurol. Neurosurg. Psychiatry. 2018;89:1088–1100. doi: 10.1136/jnnp-2017-317440. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources